Education
About Us
Working with TipRanks
Follow Us
Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
KPTI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.51 - $16.96
Previous CloseN/A
Volume220.82K
Average Volume (3M)197.76K
Market Cap
$64.69M
Enterprise Value$176.07M
Total Cash (Recent Filing)$38.73M
Total Debt (Recent Filing)$94.80M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Oct 30, 2025EPS Estimate
-3.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.32
Shares Outstanding8,671,278
10 Day Avg. Volume294,787
30 Day Avg. Volume197,761
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap2.72
Enterprise Value/Revenue1.28
Enterprise Value/Gross Profit1.33
Enterprise Value/Ebitda-2.29
Forecast
1Y Price Target
$18.25Price Target Upside133.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressNew data from the Phase II XPORT-MF-035 study showed signs of spleen volume reduction and symptom improvement in pretreated myelofibrosis patients.
Regulatory ApprovalXpovio previously received FDA Fast Track Designation for the treatment of patients with myelofibrosis.
Revenue PotentialKaryopharm estimates a peak revenue opportunity of $1 billion for Xpovio in myelofibrosis.
Bears Say
Cash Runway ConcernsThe company is working under a constrained cash runway.
Revenue DeclineKPTI reported net product revenue of $21.1M for Xpovio, which was below consensus estimates and down approximately 28% from the previous quarter.
Workforce ReductionKaryopharm announced that it would be reducing its workforce by roughly 20% after confidential discussions with potential investors regarding potential financing transactions failed to yield any results.
Karyopharm Therapeutics News
KPTI FAQ
What was Karyopharm Therapeutics’s price range in the past 12 months?
Karyopharm Therapeutics lowest stock price was $3.51 and its highest was $16.96 in the past 12 months.
What is Karyopharm Therapeutics’s market cap?
Karyopharm Therapeutics’s market cap is $64.69M.
When is Karyopharm Therapeutics’s upcoming earnings report date?
Karyopharm Therapeutics’s upcoming earnings report date is Oct 30, 2025 which is in 62 days.
How were Karyopharm Therapeutics’s earnings last quarter?
Karyopharm Therapeutics released its earnings results on Aug 11, 2025. The company reported -$4.32 earnings per share for the quarter, missing the consensus estimate of -$4.082 by -$0.238.
Is Karyopharm Therapeutics overvalued?
According to Wall Street analysts Karyopharm Therapeutics’s price is currently Undervalued.
Does Karyopharm Therapeutics pay dividends?
Karyopharm Therapeutics does not currently pay dividends.
What is Karyopharm Therapeutics’s EPS estimate?
Karyopharm Therapeutics’s EPS estimate is -3.4.
How many shares outstanding does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 8,671,278 shares outstanding.
What happened to Karyopharm Therapeutics’s price movement after its last earnings report?
Karyopharm Therapeutics reported an EPS of -$4.32 in its last earnings report, missing expectations of -$4.082. Following the earnings report the stock price went down -4.315%.
Which hedge fund is a major shareholder of Karyopharm Therapeutics?
Currently, no hedge funds are holding shares in KPTI
Karyopharm Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.25 (133.67% Upside)
$18.25 (133.67% Upside)
Hedge Fund Trend
Decreased
By 8.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.42%
12-Months-Change
Fundamentals
Return on Equity
41.08%
Trailing 12-Months
Asset Growth
-50.99%
Trailing 12-Months
Company Description
Karyopharm Therapeutics
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
KPTI Company Deck
KPTI Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive progress in clinical trials and commercial performance, especially with a steady increase in revenue from XPOVIO and global expansion efforts. However, significant financial challenges due to a net loss, decline in total revenue, and approaching debt maturity are concerning. The company is actively working on strategic alternatives to enhance liquidity.View all KPTI earnings summariesKPTI Stock 12 Month Forecast
Average Price Target
$18.25
▲(133.67% Upside)
Technical Analysis
X4 Pharmaceuticals
―
Connect Biopharma Holdings
―
Werewolf Therapeutics
―
PepGen Inc.
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
9.38% Insiders
34.80% Mutual Funds
26.16% Other Institutional Investors
25.46% Public Companies and
Individual Investors